Gait Training Systems in Colorado

Exer Labs develops an FDA-registered Class II medical device software platform that delivers AI-powered motion analysis and clinical decision support for musculoskeletal and movement disorders. The platform captures objective movement data via smartphone or tablet cameras (no wearables required) in clinic and home settings, applying proprietary neural networks to generate real-time insights on gait, joint mobility, hand/wrist function, and functional movement patterns. The system is HIPAA-compliant and integrates with existing EHR workflows via barcode scanning and APIs. Primary clinical applications include orthopedics (major joints, hand, wrist), neurology (Parkinson's, digital movement evaluation), physical medicine and rehabilitation (personalized treatment planning), senior living (fall risk detection and prevention), and primary care (early intervention and objective outcome tracking). The platform features in-clinic capture apps, at-home patient monitoring via mobile app, real-time clinician dashboards, automated billing reports, and standardized outcome measures. Exer's AI is wholly proprietary and internally trained. Clinical validation includes collaborations with Mayo Clinic (hand and wrist disorders), Wake Orthopedics, and Legacy Healthcare (senior living), with demonstrated accuracy compared to traditional goniometry. The solution addresses provider workflow integration, remote monitoring capabilities, and cost optimization through reduction of unnecessary diagnostic testing and improved care coordination across inpatient, outpatient, and home-based care settings.

UltraThera Technologies, Inc. manufactures GyroStim, an FDA-cleared Breakthrough Device for multimodal neurorehabilitation. GyroStim is a precision neurotechnology platform engineered to accelerate recovery from concussion, mild traumatic brain injury (mTBI), and vestibular dysfunction. The device combines rotational motion with precisely dosed therapeutic protocols to address balance disorders and neurological impairments. Clinical evidence demonstrates up to 8× faster rehabilitation rates compared to conventional therapy alone. FDA-cleared under K220231 for treatment of balance disorders and vestibular dysfunction, GyroStim holds the rare FDA Breakthrough Device designation, recognizing its capability to significantly advance standard-of-care outcomes. The system has been in continuous clinical use since 2010 with zero reported injuries. GyroStim is accessible to patients across a broad severity spectrum, including those with severe physical or cognitive disabilities who may not tolerate traditional therapies. The platform is used by elite athletes, military personnel, civilians, and patients in specialized neurorehabilitation centers worldwide. Applications include sports-related concussion recovery, traumatic brain injury rehabilitation, vestibular rehabilitation, and performance optimization. The company provides clinical outcome data, physician training, and patient support services. Manufacturing and regulatory compliance align with medical device standards for rehabilitation and neurological therapeutic equipment.